SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wallace, D J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallace, D J
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Apheresis for lupus erythematosus: state of the art

D J Wallace

Cedars-Sinai/UCLA School of Medicine, Los Angeles, CA 90048, USA; 8737 Beverly Blvd, Suite 203, Los Angeles, CA 90048, USAdwallace{at}ucla.edu

PP is a safe, expensive, labor-intensive procedure. Its absolute SLE indications include hyperviscosity, cryoglobulinemia, pulmonary hemorrhage and TTP. PP may be useful in cyclophosphamide-resistant, serious, organ-threatening disease. It may be potentially useful in the antiphospholipid syndrome or mothers or children at risk for congenital heart block. Refinements in apheresis technology may expand the indications for PP.

Key Words: plasmapheresis

Lupus, Vol. 10, No. 3, 193-196 (2001)
DOI: 10.1191/096120301671920760
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Intensive Care MedHome page
S. K. Vora, R. A. Asherson, and D. Erkan
Catastrophic Antiphospholipid Syndrome
J Intensive Care Med, May 1, 2006; 21(3): 144 - 159.
[Abstract] [PDF]

Home page
 LupusHome page
C Pagnoux, J-M Korach, and L Guillevin
Indications for plasma exchange in systemic lupus erythematosus in 2005
Lupus, November 1, 2005; 14(11): 871 - 877.
[Abstract] [PDF]

Home page
 Ann Rheum DisHome page
G H Stummvoll, M Aringer, J S Smolen, S Schmaldienst, E Jimenez-Boj, W H Horl, W B Graninger, and K Derfler
IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study
Ann Rheum Dis, July 1, 2005; 64(7): 1015 - 1021.
[Abstract] [Full Text] [PDF]


Advertisement